Sun Pharmaceutical Industries has officially addressed and denied market rumors regarding a potential $10 billion acquisition of Organon. The pharmaceutical giant has issued a clear statement refuting the speculative reports that had been circulating in the market.

Company's Official Response

The company has categorically stated that the information regarding the alleged acquisition is speculative in nature. Sun Pharmaceutical Industries emphasized that no significant corporate event has occurred that would require mandatory disclosure to the stock exchanges or regulatory authorities.

Market Speculation Clarification

The denial comes as a direct response to rumors that had suggested the Indian pharmaceutical major was considering a substantial acquisition deal worth $10 billion. The company's statement aims to provide clarity to investors and market participants who may have been influenced by the unsubstantiated reports.

Regulatory Compliance

By issuing this clarification, Sun Pharmaceutical Industries has demonstrated its commitment to maintaining transparency with stakeholders and ensuring compliance with disclosure norms. The company has made it clear that when any material corporate action or significant event occurs, appropriate disclosures will be made in accordance with regulatory requirements.

Sun Pharmaceutical Industries Ltd has officially denied speculation regarding a potential $10 billion acquisition of US-based Organon, responding to BSE's rumour verification inquiry with a formal clarification that the reports are speculative in nature. The company's response comes after widespread media coverage suggested India's largest drugmaker was evaluating the transformative acquisition that would have marked nearly a decade since Sun Pharma's last major acquisition of Ranbaxy.

Official Company Response to BSE

In a formal communication dated January 19, 2026, Sun Pharma's Company Secretary and Compliance Officer Anoop Deshpande addressed BSE Surveillance regarding news reports about the proposed Organon acquisition. The company categorically stated that the information in media articles is speculative and confirmed no material event or information requires disclosure under Regulation 30 of the Listing Regulations.

Background of Acquisition Speculation

The speculation centered around a potential $10 billion acquisition of Organon, a women's health specialist spun out by MSD (Merck Sharp & Dohme) in 2021. The proposed transaction was reported to include debt and would have positioned Sun Pharma for significant expansion in the US market, particularly in women's health products and biosimilars.

Organon's financial position includes significant inherited debt of $9.50 billion from its 2021 spinoff, with the company actively pursuing divestments to improve its balance sheet. The company's stock experienced volatility, declining from peaks of $17-18 in November 2024 to $8.76, though it surged 28.10% amid acquisition speculation.

Sun Pharma's Current US Market Position

Sun Pharma maintains a strong presence in the US market with its innovative products portfolio reaching $1.21 billion, driven by flagship plaque psoriasis brand Ilumya. The company has established positions in dermatology, onco-dermatology, and ophthalmology through strategic acquisitions including Checkpoint Therapeutics for $416 million and Concert Pharma for $576 million.

Regulatory Compliance and Governance

The company emphasized its commitment to maintaining highest standards of governance and disclosures, stating it will keep stock exchanges informed of any material events as required under Regulation 30 of the Listing Regulations. This response demonstrates Sun Pharma's adherence to regulatory requirements and transparent communication with stakeholders regarding market speculation.